Manages nasal symptoms of perennial nonallergic rhinitis. ANDA 78492, held by Chartwell Rx. Fluticasone Propionate.
As of Nov 16, 2026, ANDA 78492 (Fluticasone Propionate), held by Chartwell Rx, was first approved by FDA on Jan 9, 2012, with 2 approved supplements and 0 published complete response letters.
Fluticasone Propionate Nasal Spray, USP 50 mcg per spray is indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 9, 2012 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Fluticasone Propionate0.05MG/SPRAY · spray, metered;nasal | Fluticasone Propionate | Rx |
| Jul 18, 2025 | Supplement 13Labeling · Standard review | Approved | None posted |
| Mar 14, 2016 | Supplement 5Labeling · Standard review | Approved | None posted |
| Jan 9, 2012 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters